 |
160 Products |  |
813 Diseases | | 160 Products |
|
1608 Trials |  |
78055 News |  |
| «12...1213141516171819202122...903904» |
- Ibrance (palbociclib) / Pfizer
Prognostic profiling of hormone receptor () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4102;
The SCA developed in this analysis confirmed findings from the PACE prospective trial and highlighted a differential prognostic impact of ctDNA features across treatment subgroups. These results provide valuable insights for personalized treatment algorithms and could guide therapeutic decisions and future clinical trial design.
- Prolia (denosumab) / Amgen
Denosumab monotherapy versus bisphosphonate switching in breast cancer bone metastases: A real-world cohort study on skeletal events and safety. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4095;
Early denosumab initiation after bone-metastasis diagnosis may lead to better clinical outcomes. These findings suggest that patients who receive denosumab promptly as the primary treatment for bone metastases may have greater benefits.
- Clinical investigators' (CIs) practice patterns for patients with hormone receptor-positive metastatic breast cancer (HR+ mBC) harboring PI3K/AKT/PTEN pathway abnormalities (PAPm). () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4093;
Future work is needed to explore how other factors (eg, age, comorbidities, HER2-low status) and rapidly emerging clinical trial findings (eg, EMBER-3) affect decision-making. A = anastrozole; IPF = inavolisib + palbociclib + fulvestrant; F = fulvestrant; AI = aromatase inhibitor; C = capivasertib; Alp = alpelisib; E = elacestrant
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Clinical factors affecting clinical investigators' (CIs) selection of CDK4/6 inhibitors (CDKis) for patients with hormone receptor-positive metastatic breast cancer (HR+ mBC). () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4092;
It would be interesting and relevant to explore whether matching approaches are being undertaken in community oncology practice. R = ribociclib; AI = aromatase inhibitor; P = palbociclib; A = abemaciclib; MI = myocardial infarction
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Efficacy of CDK4/6 inhibitors post-chemotherapy in HR+ HER2- metastatic breast cancer patients: Real-world study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4079;
The retrospective nature of this study introduces potential biases, including patient selection and inherently more aggressive disease biology that may have influenced the decision to use chemotherapy in the first line. Further analyses are necessary to clarify these findings.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Tolerance to CD4/6 inhibitor therapy as first line therapy among ER+ patients with metastatic breast cancer. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4062;
First-line therapies included palbociclib (54.9%), ribociclib (10.9%), and abemaciclib (9.7%). Racial disparities in treatment patterns and outcomes, including shorter therapy durations for Black patients, underscore the need for personalized strategies and equitable care in metastatic breast cancer.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Real-world data on the effectiveness and toxicity of CDK 4/6 inhibitors combined with hormonal therapy in patients with metastatic hormone receptor-positive and HER2-negative breast cancer in first- and second-line treatments within the Costa Rican health care system. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4058;
The data suggest that if palbociclib is used, it should ideally be initiated in the first-line setting to optimize clinical benefit. Continued research and regional data are crucial for refining treatment strategies.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Efficacy and safety of dalpiciclib plus fulvestrant and pyrotinib in HR+, HER2-low advanced breast cancer following CDK4/6 inhibitor and aromatase inhibitor: A Bayesian optimal phase ? trial. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4057;
P2
Among these patients, 21 (70.0%) received abemaciclib, and 10 (33.3%) received palbociclib and ribociclib. Our results indicated that dalpiciclib plus fulvestrant and pyrotinib achieves promising efficacy and safety in in HR+, HER2-low advanced BC patients following CDK4/6i and AI treatment.
- Prolia (denosumab) / Amgen
Diagnostic value of PET-CT for early detection of MRONJ in breast cancer patients. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4056;
These results are highly relevant for clinical practice as many patients receive regular PET/CTs and this provides the opportunity to detect MRONJ with a lead time that allows for early intervention. Presence of jaw lesion *These values were adjusted assuming disease prevalence of 11.6% according to Brunner et al JCO August 2024, https://doi.org/10.1200/JCO.24.00171
- Ibrance (palbociclib) / Pfizer
A retrospective, multicentric, observational, real-world evidence (RWE) study on cost impact, efficacy, and safety of generic palbociclib in HR+ve, HER2-ve metastatic breast cancer: An Indian perspective. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4054;
It improves progression-free survival, response rates, and affordability. The substantial cost reduction significantly alleviates the financial burden on patients, improving treatment accessibility.
- Ibrance (palbociclib) / Pfizer
Real world evidence on effectiveness of palbociclib in Indian patients with breast cancer: A single centre, investigator-initiated, retrospective study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4041;
BC. Baseline demographics
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Efficacy and safety of CDK4/6 inhibitors in HER2-positive breast cancer: A systematic review and meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4037;
However, they are not yet standard treatment. Further studies are needed to confirm these findings and establish optimal treatment protocols.
- Ibrance (palbociclib) / Pfizer
Real-world data analysis of safety and efficacy of palbociclib in HR positive, HER-2 negative MBC patients, at tertiary care hospital at Middle East, Saudi Arabia. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4030;
Neutropenia was the most frequent adverse event, requiring dose adjustments. These findings emphasize the need for proactive monitoring and management of neutropenia in this population.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Outcomes with CDK4/6 inhibitor in metastatic hormone receptor () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4028;
The OS and PFS reported are similar to real-world studies even though the complete remission rates and adverse events were lower than western data which could be attributed to difference in tumor biology. There is no difference in survival with use of CDKi in first line versus subsequent lines.
- Ibrance (palbociclib) / Pfizer, Bavencio (avelumab) / EMD Serono
Spatial transcriptomic analysis of the ImmunoADAPT trial: Neoadjuvant endocrine therapy combined with palbociclib and avelumab in early-stage ER-positive breast cancer. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_3989;
P2
Our results align with preclinical data showing that CDK4/6 inhibitors can upregulate adaptive immune cascades in the tumor microenvironment, including Ag presentation, T cell recruitment and activation. In our trial, the patients who responded to PETA were the ones who achieved an immune upregulation at C2D1 after treatment with palbociblib+ET.
- Stivarga (regorafenib) / Bayer
Phase Ib study of the combination of regorafenib with conventional chemotherapy in patients with newly diagnosed multi-metastatic Ewing sarcoma: The Rego-Inter-Ewing-1 study. (S100bc) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3825;
P1
The efficacy of the addition of regorafenib to standard multimodal treatment in newly diagnosed patients with metastatic Ewing sarcoma will be tested in the Inter-Ewing-1 trial developed by the Euro Ewing Consortium (planned initiation in Q3 2025). Recruitment to the Rego-Inter-Ewing-1 continues at DL1 (maximum 24 patients), until Inter-Ewing-1 initiates.
- ZL-1310 / ZAI Lab
ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update. (Hall A - Posters and Exhibits; Poster Bd #: 356) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3657;
P1
ZL-1310 demonstrated a tolerable safety profile and promising antitumor activity in r/r ES-SCLC, including pts with brain metastases, pt with prior tarlatamab, and in the setting of low DLL3 expression. Updated data, including patients in the randomized Part 2 dose optimization, will be presented.
- Stivarga (regorafenib) / Bayer
Regorafenib response prediction in metastatic colorectal cancer by a novel genomic and transcriptomic model. (Hall A - Posters and Exhibits; Poster Bd #: 450) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3603;
This novel predictive model successfully identified and validated molecular features associated with Rego-response in CRC. The transcriptomic and genetic signature holds significant potential for improving personalized treatment strategies by identifying patients most likely to benefit from Rego and prevents unnecessary Rego-associated toxicities in non-responders.
- Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
Discovery of potent degraders of pan-KRAS based on a novel KRAS binder. (Hall A - Posters and Exhibits; Poster Bd #: 428) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3560;
The innovative linker elongation and branching, coupled with modifications of KRAS binder portion significantly contributed to potent pan-KRAS degraders, which demonstrate excellent pharmacokinetics and exhibit remarkable efficacy both in vitro and in vivo. The IND-enabling studies are being conducted and the regulatory IND filing will be completed in 2025.
- IMC001 / Immunofoco, Stivarga (regorafenib) / Bayer
A phase 1, first-in-human study of regorafenib plus temozolomide with or without radiotherapy in patients with newly diagnosed MGMT methylated, IDHwt glioblastoma: The REGOMA-2 trial. (Hall A - Posters and Exhibits; Poster Bd #: 114) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3500;
P1
The MTD of 120mg can be considered the recommended dose of REG in combination with standard Stupp therapy for the phase 2 study. Preliminary activity analyses are ongoing.
- Stivarga (regorafenib) / Bayer
Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: The MIRAGE trial. (Hall A - Posters and Exhibits; Poster Bd #: 141a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3479;
P2
MIRAGE, initiated in September 2024, is an academic trial promoted by the Istituto Oncologico Veneto, IOV-IRCCS and will recruit patients across 15 neuro-oncology Centers in Italy with an estimated study duration of 18 months. MIRAGE is the first randomized phase 2 trial analyzing the role of a RTK inhibitor (regorafenib) in prolonging PFS in pts with grade 2-3 meningioma who are ineligible for further surgery and/or radiotherapy.
- Itovebi (inavolisib) / Roche
INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2 (Hall B1) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3419;
P2/3
Improvement in INV-PFS was maintained during longer follow-up, along with a substantial and statistically significant improvement in ORR. TTC was also substantially delayed (by ~2 years) by the addition of INAVO to PALBO + FULV.
- Itovebi (inavolisib) / Roche
Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy (Hall B1) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3418;
P1
Clinical Trial Registration Number: NCT03006172 Background: INAVO, a highly potent and selective PI3K? inhibitor that also promotes degradation of mutated p110?, is approved by the FDA in combination with PALBO + fulvestrant (FULV) for PIK3CA-mutated, HR+, HER2
- Ibrance (palbociclib) / Pfizer
Prospective cohort study of palbociclib in HR+/HER2- metastatic breast cancer in Japan. (Hall A - Posters and Exhibits; Poster Bd #: 35) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3397;
P=N/A
Although the background of each cohort needs to be further investigated, the PFS2 result of Cohort B was excellent and the subsequent 3-year OS of this cohort was satisfactory. Based on these results, the use of PAL in the 2nd line setting may be clinically acceptable.
- Itovebi (inavolisib) / Roche
Phase Ib study of inavolisib (INAVO) + weekly paclitaxel (wP) in patients (pts) with locally advanced/metastatic (LA/m) incurable solid tumors: Safety, pharmacokinetics (PK), and preliminary antitumor activity. (Hall A - Posters and Exhibits; Poster Bd #: 41) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3389;
Based on these results, the use of PAL in the 2nd line setting may be clinically acceptable. However, it has an unfavorable benefit
- PMD-026 / Phoenix Molecular Designs
Dauntless-1, a phase 2 clinical trial to evaluate PMD-026, a first-in-class pan-RSK inhibitor, combined with fulvestrant to overcome resistance to CDK4/6 inhibitors in advanced or metastatic HR+/HER2- breast cancer. (Hall A - Posters and Exhibits; Poster Bd #: 104a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3387;
P1/2
Secondary objectives include duration of response, overall response and overall survival. Exploratory objectives will evaluate PMD-026 in the context of mutations (ESR1, PIK3CA, AKT1, p53, KRAS) at baseline using ctDNA.
- Orserdu (elacestrant) / Menarini
Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study. (Hall A - Posters and Exhibits; Poster Bd #: 58) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3374;
P1/2
Elacestrant has the potential to become an ET backbone for multiple targeted agents, providing an all-oral treatment option in pts with ER+/HER2- mBC, delaying chemo or ADC-based regimens. Treatment-emergent AEs (?30%).*Combined terms;
- SCR-6852 / Simcere
SIM0270 in combination with palbociclib in patients with ER+/ HER2- advanced breast cancer: The phase Ib study. (Hall A - Posters and Exhibits; Poster Bd #: 47) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3362;
P1
6 months in advanced setting; ?2 prior chemotherapies in advanced setting; and prior fulvestrant was allowed. SIM0270 in combination with palbociclib showed acceptable safety and tolerability, promising clinical activity in patients with ER+/HER2- advanced breast cancer.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Overall survival in patients with HR+/HER2- advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus an aromatase inhibitor: A US Food and Drug Administration pooled analysis. (Hall A - Posters and Exhibits; Poster Bd #: 34) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3359;
Additional research is needed to determine which subgroup of patients may benefit more or less of the addition of a CDKI to AI. Additional clinicopathologic subgroup analyses conducted with results not shown.
- Orserdu (elacestrant) / Menarini
Elacestrant (Ela) combinations with ribociclib (Ribo) and everolimus (Eve) in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study. (Hall A - Posters and Exhibits; Poster Bd #: 49) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3352;
P1/2
Ela 345 mg + Ribo 400 mg QD was determined as the RP2D. Previously, Ela 345 mg + Eve 7.5 mg was identified as the RP2D.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Effectiveness comparison of palbociclib, ribociclib and abemaciclib in patients with HR+/HER2- aBC: Updated results from the real-world, Italian study PALMARES-2. (Hall A - Posters and Exhibits; Poster Bd #: 53) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3338;
The three CDK4/6i have different effectiveness in HR+/HER2- aBC pts. Longer follow-up of PALMARES-2 study and more pts/events in the A cohort are needed to perform definitive OS comparisons between P, R and A.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Impact of body weight and body composition on survival and toxicities in patients receiving CDK4/6 inhibitors for ER+/HER2- metastatic breast cancer. (Hall A - Posters and Exhibits; Poster Bd #: 66) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3308;
Early changes in skeletal density during CDK4/6 inhibitors treatment is a potential predictor of improved outcomes. Muscle area is a potential predictor of treatment toxicities.
- Ibrance (palbociclib) / Pfizer
Thymidine kinase activity (TKa) as independent predictor of outcome in metastatic breast cancer (MBC) patients in the GEICAM/2013-02 PEARL trial. (Hall A - Posters and Exhibits; Poster Bd #: 45) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3291;
P3
The original PEARL study analysis showed no outcome differences between Cape vs ET + Palbo in HR+/HER2- MBC pts, however assessment of TKa before and during therapy identified which patients had the highest probability of responding. Utilization of TKa as a predictive biomarker may allow for better personalized treatment selection.
- Impact of venous thromboembolism on survival in multiple myeloma patients receiving bispecific antibody therapy: Insights from real-world data. (Hall A - Posters and Exhibits; Poster Bd #: 89) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2935;
RWD demonstrated that MM patients treated with BsAbs who developed VTE had a higher risk of death and shorter overall survival. Further analysis, possibly evaluating patient-level data on a larger cohort of patients with more sophisticated confounding controls, is needed to further clarify this finding.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Overall survival (OS) and duration of response for transfusion independence (TI) in erythropoiesis stimulating agent (ESA) (E450a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2883;
P3
LUSPA signifies a new standard of care for anemia in first-line LR-MDS. ITT, intention-to-treat; U, units.
- Scemblix (asciminib) / Novartis, Blincyto (blinatumomab) / Astellas, Amgen
A phase I study of asciminib in combination with dasatinib, prednisone, and blinatumomab for Ph-positive acute leukemia in adults. (E450a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2880;
P1
An additional 25-pt cohort is planned with blin in combination with DAS and ASC at optimized doses. Response kinetics.
- BTI615 / Chengdu Brilliant Pharma
Efficacy of BTI615 on malignant cells expansion and bone marrow fibrosis in a myelofibrosis mice model. (Hall A - Posters and Exhibits; Poster Bd #: 188) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2867;
Given its effective suppression on hyperplasia of atypical megakaryocytes, inflammation, marrow fibrosis and the ultimate recovery of hematopoietic function via modulating TGF-? signaling, BTI615 has a great potential to be the next generation therapeutic approach for MF.
- Monjuvi (tafasitamab-cxix) / Incyte, Rituxan (rituximab) / Roche
Initial results from a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) (Hall A - Posters and Exhibits; Poster Bd #: 156) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2851;
P2
The addition of blinatumomab to frontline chemotherapy improves survival, but regimens used are limited by toxicity and complexity. In a cohort of ND Ph- B-ALL, the addition of tafa to DA-EPOCH
- Venclexta (venetoclax) / Roche, AbbVie, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer
Outcomes of Ph-like B-lineage acute lymphoblastic leukemia in the era of novel therapies. (Hall A - Posters and Exhibits; Poster Bd #: 151) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2830;
Adding novel agents (InO, blin, venetoclax) to upfront regimens may improve outcomes. Future studies should focus on optimal first-line combinations and higher-risk groups such as KRAS-mutated Ph-like B-ALL.
- Aucatzyl (obecabtagene autoleucel) / Autolus
Efficacy and safety outcomes of obecabtagene autoleucel (obe-cel) stratified by age in patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). (Hall A - Posters and Exhibits; Poster Bd #: 192) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2825;
P1/2
Obe-cel treatment resulted in favorable ORR and EFS with low Grade ?3 CRS/ICANS incidence in both age groups. These findings indicate that obe-cel is effective and has a positive benefit/risk profile regardless of age, including in older adults with R/R B-ALL despite few receiving consolidative SCT.
- Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer
Impact of TP53 mutations and variant allelic frequency on survival in adults with newly diagnosed acute lymphoblastic leukemia. (Hall A - Posters and Exhibits; Poster Bd #: 160) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2816;
VAF ?45% can risk stratify pts aged ?60 years but did not impact OS in younger pts. Incorporating frontline InO and/or Blina into therapy might improve outcomes of TP53-mutated ALL.
- Stivarga (regorafenib) / Bayer
Efficacy and safety of regorafenib combination with PD-1 inhibitors vs. regorafenib monotherapy in second-line treatment for patients with unresectable hepatocellular carcinoma after failure of different first-line treatments: A multicenter retrospective real-world study. (Hall A - Posters and Exhibits; Poster Bd #: 378) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2521;
However, in patients who have progressed after first-line TKI plus PD-1 therapy, using regorafenib alone or in combination with PD-1 in second-line therapy does not show a significant difference in efficacy. These findings have significant implications for the selection of second-line treatment strategies for HCC patients, indicating that the combination of regorafenib and PD-1 might not provide additional benefits in certain patient subgroups.
- Imdelltra (tarlatamab-dlle) / Amgen
Administration of tarlatamab in an outpatient setting utilizing remote patient monitoring: Mayo Clinic experience. (Hall A - Posters and Exhibits; Poster Bd #: 418) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2410;
Our experience shows that frequent monitoring required with tarlatamab can be safely and effectively executed in an outpatient setting with the utilization of an RPM system. It can potentially minimize the burden of hospitalizations for patients and the healthcare system.
- Prolia (denosumab) / Amgen
Pilot study of an enhanced telehealth program for patients with prostate cancer. (Hall A - Posters and Exhibits; Poster Bd #: 413) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2365;
Patients found ET for the management of prostate cancer on ADT to be feasible, acceptable, and appropriate, providing a more patient-centered and convenient alternative to traditional clinic-based care. Future studies will explore scalability and applicability across diverse patient populations and treatment regimens.
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical implications and prevalence of benign ethnic neutropenia (BEN) in breast cancer patients of Middle Eastern ethnicity. (Hall A - Posters and Exhibits; Poster Bd #: 367) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2326;
Duffy phenotyping can be used in place of more invasive tests to identify these patients. Treatment delays due to apparent neutropenia are common, however, response to filgrastim is universal, and febrile neutropenia episodes are rarely seen.
- Ibrance (palbociclib) / Pfizer
Circulating tumor (ct)DNA monitoring of ER+/HER2- high-risk breast cancer during adjuvant endocrine therapy. (Arie Crown Theater) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2256;
P2
Patients with serially ctDNA- results during surveillance had 99% RFS after a median f/u of 27.4 months. Interim analysis revealed higher clearance rates in Arm A compared to patients randomized to Arm B. Early on treatment ctDNA dynamics is prognostic of patient outcomes.
- Prolia (denosumab) / Amgen
Prospective observational study on health resource utilization and patterns of care for skeletal-related events in patients with bone metastases secondary to solid tumors. (Hall A - Posters and Exhibits; Poster Bd #: 72) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2224;
Post-SRE BMA use was associated with improved outcomes, underscoring the need for earlier initiation of BMA therapy. Future research should focus on identifying barriers to early BMA utilization, optimizing management of therapy-related complications, and assessing the cost-effectiveness of BMAs in real-world settings.
- Imdelltra (tarlatamab-dlle) / Amgen, Zepzelca (lurbinectedin) / PharmaMar, Jazz
Comparison of outcomes for patients diagnosed with small cell lung cancer between a university and safety net hospital. (Hall A - Posters and Exhibits; Poster Bd #: 97) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2171;
This difference may reflect the referral patterns for patients with complex SCLC presentations to an academic cancer center. More SDH was identified at UH.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
CDK4/6 inhibitor toxicity in geriatric subgroups: Evidence from the FAERS database. (Hall A - Posters and Exhibits; Poster Bd #: 146) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2132;
Our findings demonstrated that liver toxicity was lower across all geriatric age subgroups, and hematological toxicity was reduced only in 75-84 age group. There were no significant differences in GI toxicities among the age subgroups.
- Nplate (romiplostim) / Amgen
Romiplostim for chemotherapy?induced thrombocytopenia (CIT) in colorectal, gastroesophageal, and pancreatic cancers: A global, phase 3, randomized, placebo-controlled trial (RCT). (S100bc) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2112;
P3
There were no significant differences in GI toxicities among the age subgroups. This was a phase 3, placebo (PBO)-controlled RCT of patients receiving oxaliplatin?based multiagent regimens for GI cancers with persistent CIT, ie platelets (Plt) ?85